.jpg?format=webp&width=780)
Therapeutic strategies using the immune system against cancer show promise for non-small-cell lung cancer (NSCLC) patients. Immune-checkpoint inhibitors (ICIs) have demonstrated success in advanced-stage NSCLC, but their use in early-stage NSCLC is hindered by the lack of robust evaluation methods. Trials are underway to test ICIs alone or with chemotherapy in neoadjuvant settings. The primary endpoint is now focused on pathological response. Despite approval in adjuvant and neoadjuvant settings, the correlation with overall survival remains unclear.
Like
Save
Share